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2004, 2005–2008 and 2009–2012.  Results: From 996 (53% 
female) PH patients, 549 had pulmonary arterial hyperten-
sion (PAH), 36 PH due to left heart disease, 127 due to lung 
disease, 249 to chronic thromboembolic PH (CTEPH) and 35 
to miscellaneous PH. Age and BMI significantly increased 
over time, whereas hemodynamic severity decreased. Over-
all, event-free survival was 84, 72, 64 and 58% for the years 
1–4 and similar for time periods since 2000, but better dur-
ing the more recent periods for PAH and CTEPH. Of all PAH 
cases, 89% had target medical therapy and 43% combina-
tion therapy. Of CTEPH patients, 14 and 2% underwent pul-
monary endarterectomy or transplantation, respectively; 
87% were treated with PAH target therapy.  Conclusion: 
Since 2000, the incident Swiss PH patients registered were 
older, hemodynamically better and mostly treated with PAH 
target therapies. Survival has been better for PAH and CTEPH 
diagnosed since 2008 compared with earlier diagnosis or 
other classifications.  © 2015 S. Karger AG, Basel 
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 Abstract 
 Background: Registries are important for real-life epidemi-
ology on different pulmonary hypertension (PH) groups.  Ob-
jective: To provide long-term data of the Swiss PH registry of 
1998–2012.  Methods: PH patients have been classified into 
5 groups and registered upon written informed consent at 5 
university and 8 associated hospitals since 1998. New York 
Heart Association (NYHA) class, 6-min walk distance, hemo-
dynamics and therapy were registered at baseline. Patients 
were regularly followed, and therapy and events (death, 
transplantation, endarterectomy or loss to follow-up) regis-
tered. The data were stratified according to the time of diag-
nosis into prevalent before 2000 and incident during 2000–
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 Introduction 
 Pulmonary hypertension (PH) is classified into 5 ma-
jor groups  [1, 2] . Group I or pulmonary arterial hyperten-
sion (PAH) might be idiopathic, hereditary or associated 
with different disorders. Group II involves the postcapil-
lary PH forms due to left heart diseases. Group III encom-
passes PH due to chronic hypoxemic lung diseases, group 
IV chronic thromboembolic PH (CTEPH) and group V 
PH due to unclear/multifactorial mechanisms. Many 
forms of PH share a final common pathway and response 
to treatment  [3, 4] . CTEPH is mostly preceded by venous 
thromboembolism and might be cured by surgical endar-
terectomy in selected patients  [5] . Distal CTEPH shares 
pathogenetic and clinical features with PAH  [4, 5] .
 The epidemiology of PH is still incompletely known 
 [6] . Registries have given information on some aspects of 
the disease in different parts of the world, but only few 
registries included patients with different PH classifica-
tions  [7–14] . The first registry providing data on primary 
PH, today named idiopathic PAH, was the NIH registry 
including 194 patients from 1981 to 1988 in 32 US centers 
 [15] . Other nationwide registries followed, mainly includ-
ing patients with PAH or CTEPH, with follow-up periods 
up to 8 years  [8, 10, 16, 17] . The first long-term registry on 
different PH groups was the ASPIRE registry, a single-
center registry from Sheffield with a follow-up of up to 10 
years  [7] . Switzerland was one of the first countries to set 
up a nationwide registry in 1998, when the first prevalent 
cases were included followed by incident cases from 2000. 
The Swiss registry focused on PAH and CTEPH; however, 
the inclusion of patients with other PH classifications was 
allowed  [12, 18] . The Swiss registry has been run for  ≥ 15 
years and provides an opportunity to compare the course 
of incident patients over different time periods and to in-
vestigate the changing epidemiology of PH. 
 Methods 
 The Swiss registry was opened in 1998, and data were prospec-
tively collected in 5 university and in 8 associated hospitals. The 
registry focuses on PAH and CTEPH but allows entering data from 
all PH types confirmed by right heart catheterization. All patients 
gave their written informed consent, and the registry was approved 
by the Swiss Agency on Registries.
 Patients included in the registry were classified into 5 major 
groups. Despite changes in classification over the years, these 
groups still mainly correspond to the current classification  [1, 2, 
19] : group I = PAH including idiopathic/hereditary PAH (the two 
were not distinguished), induced by drugs and toxins, associated 
with connective tissue disease, HIV infection, portal hyperten-
sion, congenital heart diseases and others; group II = PH due to 
left heart disease; group III = PH due to lung diseases/hypoxia; 
group IV = CTEPH, and group V = miscellaneous  [1] . The clas-
sification was done according to guidelines  [20] ; all patients had 
diagnostic right heart catheterization including measurement of 
pulmonary artery wedge pressure to confirm and classify PH into 
pre- and postcapillary groups  [20] . All patients had a thorough 
clinical investigation including ventilation-perfusion scan, echo-
cardiography, pulmonary function test, thoracic computed to-
mography and/or pulmonary angiography, blood analysis and 
more according to the clinical picture to correctly classify patients 
 [19] . Each center was responsible for allocating their patients to 
one of the respective PH classifications. 
 Mandatory data at baseline were: classification, demographics, 
vital functions, functional parameters (New York Heart Associa-
tion, NYHA class; 6-min walk distance, 6MWD; Borg scale), the 
tricuspid gradient and the following hemodynamics by heart cath-
eterization: mean pulmonary artery pressure (mPAP), pulmonary 
artery wedge pressure, right atrial pressure, cardiac output, mixed 
venous oxygen saturation and vasoreactivity defined as a decrease 
in pulmonary vascular resistance (PVR)  ≥ 20% (until 2005) or 
mPAP  ≥ 10 to  ≤ 40 mm Hg. After baseline diagnosis, patients were 
regularly followed, and the following information was registered: 
PAH target therapy defined as endothelin receptor antagonists 
(ERA), phosphodiesterase inhibitors (PDE5-I) or prostanoids; 
therapy with calcium channel blockers (CCB) given for PAH was 
noted separately, and the times of events defined as death, lung 
transplantation or loss to follow-up (date last alive) such as pulmo-
nary endarterectomy were entered. 
 In 2012 the event status of every registered patient was checked, 
and data were extracted for analysis by December. Analysis was 
performed overall and separately for PAH, CTEPH and other 
groups with >100 data sets. The following time periods for analysis 
were defined: up to end of 1999 (including incident and prevalent 
cases), incident cases diagnosed in 2000–2004, 2005–2008 and 
2009–2012. Death, lung transplantation, pulmonary endarterec-
tomy and the date when the patient was last observed alive in case 
of loss to follow-up were considered as events for survival analysis. 
 Analyses were performed using SPSS Statistics version 21. Data 
are presented as means (with standard deviations) or numbers 
(with percentages). ANOVA, the t test or Mann-Whitney U test 
was used. Lifetable, Kaplan-Meier analysis and Cox regression 
were performed to compare event-free survival and impact of co-
variates overall and according to period of diagnosis. A p < 0.05 
was considered significant.
 Results 
 Overall PH Patients 
 The patients’ flowchart is shown in  figure 1 . From 
1,119 data sets retrieved from the registry, 68 had to be 
excluded as main parameters (classification or mPAP) 
were missing. Fifty-five patients did not fulfil diagnostic 
criteria. Baseline characteristics of the final 996 patients 
overall or stratified by the predefined diagnostic time pe-
riods are shown in  table 1 .
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 Over consecutive periods, fewer patients with PAH 
but more patients with other classifications were included 
( fig. 2 ). Age at diagnosis, BMI and blood pressure signif-
icantly increased over time, and mPAP and PVR de-
creased. The cardiac index remained stable over the last 3 
incident periods, whereas it was higher during the first 
period which included younger and mostly prevalent pa-
tients. In the period from 2000 to 2004, newly diagnosed 
incident cases had the worst WHO functional class ( ta-
ble 1 ). 
 The absolute follow-up time from diagnosis to the end 
of 2012 or an event ranged from 1 to 10,378 days (>28 
years). The longest follow-up was observed in a patient 
diagnosed in 1984 at the age of 37 years with idiopathic 
vasoreactive PAH, who was successfully treated with 
CCB. The percentage of lung transplantation decreased 
over time. Endarterectomy in CTEPH was rare but slight-
ly increased over time. 
 The 1- to 4-year event-free-survival over all PH groups 
was similar during the 3 incident periods, and best for the 
1,119 patients in the Swiss registry
(prevalent, from 1998 up to the end of 2012)
996 patients with PH defined
as mPAP 25 mm Hg
1,051 patients with acceptable data sets
68 patients with incomplete data sets
(mPAP or classification missing)
55 patients with mPAP <25 mm Hg
 Fig. 1. Flowchart of patient data set selection. 
 Table 1.  Overall PH classifications
Overall Before 2000 2000 – 2004 2005 – 2008 2009 – 2012 p
Demographics
Number of patients 996 39 227 365 365
Females 533 (54) 20 (51) 128 (56) 198 (54) 187 (51)
Children and adolescents (<18 years) 36 (3.6) 6 (15.4) 16 (7) 11 (3) 3 (0.8)
Age, years 58.4 ± 17.8 38.5 ± 20.1 53.0 ± 19.4 59.8 ± 16.8 62.5 ± 15.0 0.000
BMI 26.3 ± 6.4 23.9 ± 6.5 26.0 ± 8.0 26.2 ± 5.8 26.9 ± 5.9 0.045
Classification
PAH 549 (55.1) 30 (76.9) 147 (64.8) 201 (55.1) 171 (46.8)
PH due to left heart disease 36 (3.6) 1 (2.6) 2 (0.9) 12 (3.3) 21 (5.8)
PH due to lung disease 127 (12.8) 0 19 (8.4) 52 (14.2) 56 (15.3)
CTEPH 249 (25) 8 (20.5) 52 (22.9) 89 (24.4) 100 (27.4)
Miscellaneous 35 (3.5) 0 7 (3.1) 11 (3) 17 (4.7)
Characteristics
mPAP, mm Hg 46 ± 14 55 ± 16 50 ± 16 45 ± 12 44 ± 12 0.000
Cardiac index (n = 883), l/min/m2 2.5 ± 0.9 3.0 ± 1.7 2.5 ± 0.8 2.5 ± 0.8 2.6 ± 0.8 0.000
NYHA class mean (n = 864) 2.9 ± 0.7 2.8 ± 0.7 3.1 ± 0.7 2.9 ± 0.7 2.9 ± 0.7 0.01
6MWD (n = 799), m 357 ± 137 323 ± 125 362 ± 136 365 ± 133 350 ± 143 0.392
Outcome by December 31, 2012
Follow-up days 1,346 ± 1,286 4,104 ± 2,867 1,889 ± 1,402 1,464 ± 833 595 ± 416
Alive 528 (53) 19 (45) 64 (28) 176 (48) 269 (74)
Dead 329 (33) 12 (31) 124 (55) 137 (38) 56 (15)
Lung transplantation 38 (4) 5 (13) 17 (8) 12 (3) 4 (1)
Pulmonary endarterectomy 36 (4) 0 7 (3) 12 (3) 17 (5)
Lost to follow-up 65 (7) 3 (8) 15 (7) 28 (8) 19 (5)
 Data are given as means ± SD or numbers with percentages in parentheses.
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first period, where prevalent cases were registered. Cu-
mulative survival up to 12 years shows an equal survival 
for incident cases diagnosed in 2000–2012, but better sur-
vival for prevalent cases diagnosed before 2000 ( fig. 3 ).
 Overall, 68% of all patients were treated with PAH tar-
get therapy during the first 3 months after diagnosis; 
hereof 9% received combination therapy ( table 1 ). A total 
of 85% received PAH target therapy for >3 months of
the entire observation period; hereof 41% received com-
bination therapy.
 Adult Patients with PAH 
 Among the 549 patients with PAH (group I), 517 were 
 ≥ 18 years (60% women;  table 2 ). Patients diagnosed more 
recently were significantly older than those diagnosed 
earlier. Overall, 60% suffered from idiopathic PAH, with 
an increasing percentage over time. The overall mPAP 
was 48 ± 15 mm Hg and was significantly lower during 
the last periods. Other hemodynamic and blood oxygen-
ation parameters were comparable over time. Vasoreac-
tivity testing was performed in 274/517 (53%) PAH pa-
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tients. 32% of tested patients fulfilled criteria of acute va-
soreactivity, with patients diagnosed within the last 4 
years showing lower vasoreactivity (15%). 
 After an overall mean follow-up time of 1,393 ± 1,337 
days (3.8 years;  table  2 ), 191/517 patients died, 20 had 
lung transplantation and 34 were lost to follow-up. The 
overall survival at 1, 2, 3 and 4 years was 87, 77, 69 and 
64%, respectively, with a better 4-year survival for pa-
tients diagnosed in 2009–2012 compared with 2005–2008 
and 2000–2004 (73 vs. 66 and 54%, p = 0.02, 0.824 and 
0.03, respectively). The cumulative transplant-free sur-
vival for incident PAH patients diagnosed from 2000 is 
higher for more recent time periods ( fig. 4 ). 
 Table 2.  Patients with PAH
Overall Before 2000 2000 – 2004 2005 – 2008 2009 – 2012 p
Demographics
Number of patients 517 24 131 191 171
Females 309 (60) 16 (63) 83 (63) 116 (61) 95 (56)
Age, years 57 ± 16 42 ± 16 53 ± 16 59 ± 16 60 ± 15 0.000
BMI 26 ± 7 25 ± 6 27 ± 9 27 ± 6 26 ± 6 0.575
Classification
Idiopathic 308 (60) 12 (50) 65 (50) 113 (59) 102 (60)
Drug- and toxin-induced 10 (2) 2 (8) 2 (2) 4 (2) 2 (1)
Connective tissue diseases 94 (18) 5 (21) 31 (24) 30 (16) 28 (16)
HIV-associated 34 (7) 2 (8) 2 (2) 8 (4) 13 (8)
Portopulmonary 26 (5) 1 (4) 4 (3) 10 (5) 11 (6)
Congenital heart disease 41 (8) 2 (8) 13 (10) 16 (8) 10 (6)
Other (telangiectasia, storage) 7 (1) 0 4 (3) 3 (2) 0
Pulmonary veno-occlusive disease 12 (2) 0 1 (1) 7 (4) 4 (2)
Pulmonary capillary hemangiomatosis 1 (0) 0 0 0 1 (1)
Vital signs and hemodynamics
Heart rate (n = 469), bpm 82 ± 15 83 ± 14 82 ± 13 83 ± 15 81 ± 16 0.793
Tricuspid gradient (n = 331), mm Hg 67 ± 20 79 ± 23 69 ± 19 64 ± 18 68 ± 22 0.34
mPAP (n = 517), mm Hg 48 ± 15 55 ± 18 51 ± 17 46 ± 14 46 ± 12 0.000
Pulmonary artery wedge pressure (n = 466), mm Hg 12 ± 7 12 ± 8 12 ± 7 12 ± 7 12 ± 7 0.963
Right atrial pressure (n = 425), mm Hg 9 ± 4 9 ± 4 10 ± 8 9 ± 6 9 ± 8 0.511
PVR (n = 440), dyn/s/m5 753 ± 445 811 ± 431 833 ± 417 756 ± 502 680 ± 418 0.057
Cardiac index (n = 439), l/min/m2 2.5 ± 0.8 2.6 ± 0.9 2.5 ± 0.9 2.4 ± 0.8 2.6 ± 0.8 0.345
Arterial oxygen saturation (n = 445), % 93 ± 5 94 ± 4 92 ± 5 92 ± 5 93 ± 5 0.161
Mixed venous oxygen saturation (n = 399), % 63 ± 10 66 ± 12 62 ± 11 62 ± 10 64 ± 10 0.213
Vasoreactivity positive (n = 274) 88 ± 32 6 ± 40 32 ± 43 38 ± 36 12 ± 15
Functional capacity
NYHA class (n = 450)
I 5 (1) 1 (4) 1 (1) 3 (2) 0
II 109 (24) 6 (25) 23 (19) 32 (21) 48 (32)
III 259 (57) 15 (63) 73 (59) 94 (61) 77 (52)
IV 77 (17) 2 (8) 26 (21) 25 (16) 24 (16)
NYHA mean (n = 450) 2.9 ± 0.6 2.8 ± 0.7 3.0 ± 0.7 2.9 ± 0.7 2.8 ± 0.7 0.129
6MWD (n = 423), m 362 ± 137 341 ± 120 364 ± 144 360 ±133 366 ± 139 0.916
Outcome by December 31, 2012
Follow-up days 1,393 ± 1,337 4,021 ± 3,035 1,832 ± 1,379 1,483 ± 826 588 ± 420
Alive 271 (52) 12 (50) 35 (27) 94 (49) 130 (76)
Dead 191 (37) 7 (29) 79 (60) 79 (41) 26 (15)
Lung transplantation 20 (4) 4 (17) 10 (8) 4 (2) 2 (1)
Lost to follow-up 34 (7) 1 (4) 6 (5) 14 (7) 13 (8)
 Data are given as means ± SD or numbers with percentages in parentheses.
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 72% of PAH patients received first-line PAH target 
therapy within 3 months of diagnosis with increasing per-
centages over time ( table 3 ). The majority was started on 
a single drug, 10% received double and 3% triple combi-
nation therapy with an increasing percentage over time. 
1/4 of the 28% of patients who did not receive PAH target 
therapy received a high-dose CCB (overall 7%), with a 
decreasing percentage over time ( table 3 ). From patients 
diagnosed with positive vasoreactivity testing in 2000–
2004, 2005–2008 and 2009–2012, 25, 39 and 58% received 
p < 0.05 2005–2008 vs. 2000–2004
p < 0.05 2009–2012 vs. 2000–2004
p = n.s. 2009–2012 vs. 2000–2008
Time of PAH diagnosis
2000–2004
2005–2008
2009–2012
2000–2004 – censored
2005–2008 – censored
2009–2012 – censored
3650
0
0.2
0.4
0.6
0.8
1.0
730 1,095 1,460 1,825 2,190 2,555 2,920 3,285 3,650 4,015 4,380 days
1 2 3 4 5 6 7 8 9 10 11 12 years
Cu
m
ul
at
iv
e 
su
rv
iv
al
 Fig. 4. Kaplan-Meier survival curves for in-
cident PAH during different time periods. 
 Table 3.  Target therapy in patients with PAH
Overall Before 2000 2000 – 2004 2005 – 2008 2009 – 2012
Patients 517 24 131 191 171
Therapy started within 3 months
No target therapy 146 (28) 16 (63) 47 (40) 53 (28) 31 (18)
High-dose CCB 36 (7) 6 (25) 8 (6) 15 (8) 7 (4)
Single drug 303 (59) 9 (38) 72 (55) 115 (60) 107 (63)
Double combination 51 (10) 0 10 (8) 17 (9) 24 (14)
Triple combination 17 (3) 0 2 (2) 6 (3) 9 (5)
ERA 269 (52) 0 52 (40) 112 (59) 105 (61)
Prostanoids 73 (14) 9 (8) 40 (31) 12 (6) 12 (7)
PDE5-I 113 (22) 0 6 (5) 42 (22) 65 (38)
Maximal therapy 
No PAH target therapy 55 (11) 4 (17) 18 (14) 21 (11) 12 (7)
High-dose CCB 25 (5) 3 (12) 9 (7) 10 (5) 3 (2)
Single drug 236 (46) 9 (38) 55 (42) 85 (45) 87 (51)
Double combination 152 (29) 10 (42) 36 (28) 53 (28) 53 (31)
Triple combination 74 (14) 1 (4) 22 (17) 32 (17) 19 (11)
Data are numbers with percent of total in parentheses.
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first-line CCB, respectively. During follow-up, 89% of all 
patients received PAH target therapy, 29 and 14% re-
ceived double or triple combination therapy, respectively.
 Patients with CTEPH 
 All 249 patients with CTEPH were >18 years old with 
equal sex distribution ( table 4 ). Mostly, proximal/surgi-
cally accessible or distal/surgically inaccessible disease 
was not distinguished. Patients were severely compro-
mised with a mean mPAP of 45 ± 12 mm Hg, PVR of 767 
± 463 dyn/s/m 5 , NYHA/WHO class 3 ± 0.7 and 6MWD 
of 365 ± 138 m with equal limitation since 2000. The over-
all mean follow-up time of CTEPH was 1,313 days (range 
1–7,618). 14 and 2% of patients had pulmonary endarter-
ectomy or lung transplantation, respectively, 23% died 
and 6% were lost to follow-up. The overall 1-, 2-, 3- and 
4-year transplant-free survival in nonoperated CTEPH 
was 91, 84, 77 and 73%, respectively and better recently 
( fig. 5 ).
 Adult Patients with PH in Chronic Lung Disease 
 127 subjects had PH due to lung diseases, with a mean 
age of 66 ± 12 years, 31% females, all incident in 2000–
2012 ( table 5 ). 29% had obstructive and 28% interstitial 
lung diseases, a minority sleep-disordered breathing, hy-
poventilation or developmental disease. 31% were not 
further classified. Overall, mPAP was 41 ± 11 mm Hg, 
PVR 515 ± 346 dyn/s/m 5 , NYHA class 3 ± 0.7 and 6MWD 
305 ± 126 m. The transplant-free 1- to 4-year survival was 
79, 62, 52 and 45%, respectively. Overall, 71% were treat-
ed with PAH target therapy (50% single, 23% combina-
tion therapy). Kaplan-Meier analysis revealed equal sur-
vival for patients with and without PAH target therapy. 
 Differential Aspects between Different PH Groups 
 Characteristics of PH patients by diagnostic groups are 
shown in  table 5 . Patients with CTEPH were significantly 
older and more obese compared with PAH cases and had 
lower mPAP, cardiac index and arterial oxygen satura-
tion. Functional class and the 6MWD were equal in PAH 
and CTEPH. Event-free survival by Kaplan-Meier analy-
sis and lifetable was similar in PAH and CTEPH, but 
worse in PH due to lung disease and miscellaneous forms 
( table 6 ;  fig. 6 ). 
 Discussion 
 The Swiss PH registry was opened in 1998 and pro-
vides long-term data of patients seen at PH referral cen-
ters throughout Switzerland. During the first 2 years, 
prevalent and incident PH cases and from 2000 only in-
p < 0.05 2009–2012 vs. 2000–2004
Time of CTEPH diagnosis
2000–2004
2005–2008
2009–2012
2000–2004 – censored
2005–2008 – censored
2009–2012 – censored
3650
0
0.2
0.4
0.6
0.8
1.0
730 1,095 1,460 1,825 2,190 2,555 2,920 3,285 3,650 4,015 4,380 days
1 2 3 4 5 6 7 8 9 10 11 12 years
Cu
m
ul
at
iv
e 
su
rv
iv
al
 Fig. 5. Kaplan-Meier survival curves of 215 
nonoperated CTEPH patients according to 
their time of diagnosis. 
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 Table 4.  Patients with CTEPH
Overall Before 2000 2000 – 2004 2005 – 2008 2009 – 2012 p
Demographics
CTEPH 249 8 52 89 100
Females 129 (52) 2 (33) 27 (50) 50 (56) 50 (50)
Age, years 63 ± 14 49 ± 16 62 ± 13 63 ± 13 64 ± 15 0.02
BMI 27.0 ± 5.1 25.8 ± 4.1 26.9 ± 5.5 26.4 ± 4.5 27.7 ± 5.3 0.31
CTEPH classification
Proximal disease 22 (9) 1 (13) 10 (19) 3 (3) 8 (8)
Distal disease 29 (12) 3 (38) 11 (21) 4 (5) 11 (11)
Not classified 198 (80) 4 (50) 31 (60) 82 (92) 81 (81)
Vital signs and hemodynamics
Heart rate (n = 235), bpm 81 ± 14 79 ± 12 18 ± 16 78 ± 13 83 ± 14 0.132
Tricuspid gradient (n = 146), mm Hg 66 ± 18 71 ± 9 67 ± 18 64 ± 20 67 ± 16 0.728
mPAP (n = 249), mm Hg 45 ± 12 52 ± 12 47 ± 15 44 ± 10 45 ± 12 0.305
Pulmonary artery wedge pressure (n = 233), mm Hg 12 ± 6 17 ± 13 12 ± 7 11 ± 6 12 ± 4 0.06
Right atrial pressure (n = 223), mm Hg 9 ± 6 11 ± 6 9 ± 6 9 ± 5 9 ± 7 0.784
PVR (n = 218), dyn/s/m5 767 ± 463 902 ± 620 805 ± 442 765 ± 476 740 ± 457 0.798
Cardiac index (n = 227), l/min/m2 2.3 ± 0.6 2.2 ± 0.7 2.1 ± 0.4 2.4 ± 0.6 2.3 ± 0.7 0.086
Arterial oxygen saturation (n = 229), % 92 ± 4 87 ± 9 91 ± 4 93 ± 3 93 ± 4 0.0
Mixed venous oxygen saturation (n = 203), % 60 ± 10 57 ± 15 58 ± 8 59 ± 10 62 ± 11 0.149
Functional capacity
NYHA class mean (n = 228) 3.0 ± 0.7 3.4 ± 0.5 3.1 ± 0.7 2.9 ± 0.6 2.9 ± 0.7 0.109
6MWD (n = 214), m 365 ± 138 279 ± 140 356 ± 117 394 ± 133 348 ± 148 0.74
Outcome by December 31, 2012
Follow-up days until event or December 2012 1,313 ± 1,158 2,905 ± 3,046 1,911 ± 1,372 1,626 ± 797 596 ± 411
Alive (without operation) 138 (55) 1 (13) 16 (31) 50 (56) 71 (71)
Dead 58 (23) 4 (50) 23 (44) 22 (25) 9 (9)
Lung transplantation 4 (2) 1 (13) 2 (4) 1 (1) 0
PEA 34 (14) 0 6 (12) 12 (14) 16 (16)
Days until PEA 644 ± 582 – 978 ± 622 774 ± 720 421 ± 352
Lost to follow-up 15 (6) 2 (25) 5 (10) 4 (5) 4 (4)
Target therapy 
Therapy started within 3 months
No drug 68 (27) 38 (3) 14 (27) 25 (28) 26 (26)
Single drug 160 (65) 5 (63) 37 (71) 54 (61) 64 (64)
Double combination 19 (8) 0 1 (2) 9 (10) 9 (9)
Triple combination 1 (0.4) 0 0 1 (1) 0
ERA 123 (49) 0 11 (4) 49 (20) 63 (63)
Prostanoid 33 (13) 5 (2) 27 (11) 1 (0.4) 0
PDE5-I 47 (19) 0 2 (1) 25 (10) 20 (20)
Maximal therapy 
No drug 30 (12) 2 (25) 6 (12) 4 (5) 18 (18)
Single drug 110 (44) 4 (50) 19 (37) 38 (43) 49 (49)
Double combination 85 (34) 1 (13) 16 (31) 38 (43) 30 (30)
Triple combination 23 (9) 1 (13) 11 (21) 9 (10) 2 (2)
PEA = Pulmonary endarterectomy. Data are given as means ± SD or numbers with percentages in parentheses.
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 Table 5.  PH due to chronic lung diseases
Overall 2000 – 2004 2005 – 2008 2009 – 2012 p
Demographics
PH in lung disease 127 19 52 56
Females 39 (31) 6 (32) 13 (25) 20 (36)
Age, years 66 ± 12 63 ± 11 66 ± 13 67 ± 12 0.488
BMI (n = 120) 276 28 ± 5 27 ± 6 28 ± 6 0.672
Lung disease classification
Not further classified 39 (31) 4 (21) 15 (29) 20 (36)
Obstructive 37 (29) 6 (32) 15 (29) 16 (29)
Interstitial 35 (28) 7 (37) 16 (31) 12 (21)
Sleep disorders 6 (5) 1 (5) 2 (4) 3 (5)
Hypoventilation 7 (6) 1 (5) 3 (6) 3 (5)
Developmental 3 (2) 0 1 (2) 2 (4)
Vital signs and hemodynamics
Heart rate (n = 116), bpm 87 ± 20 93 ± 21 85 ± 16 86 ± 22 0.379
Tricuspid gradient (n = 76), mm Hg 61 ± 20 73 ± 27 56 ± 15 60 ± 19 0.020
mPAP (n = 127), mm Hg 41 ± 11 45 ± 12 39 ± 9 41 ± 12 0.142
Pulmonary artery wedge pressure (n = 121), mm Hg 13 ± 7 12 ± 8 14 ± 8 12 ± 5 0.202
Right atrial pressure (n = 115), mm Hg 9 ± 9 9 ± 7 8 ± 5 11 ± 12 0.167
PVR (n = 109), dyn/s/m5 515 ± 346 706 ± 388 424 ± 320 605 ± 402 0.010
Cardiac index (n = 119), l/min/m2 2.6 ± 0.6 2.6 ± 0.6 2.6 ± 0.7 2.6 ± 0.6 0.848
Arterial oxygen saturation (n = 112), % 89 ± 8 85 ± 13 90 ± 8 89 ± 5 0.052
Mixed venous oxygen saturation (n = 102), % 62 ± 11 59 ± 16 62 ± 10 62 ± 9 0.46
Functional capacity
NYHA class mean (n = 101) 3.0 ± 0.7 3.3 ± 0.7 3.1 ± 0.7 2.8 ± 0.7 0.035
6MWD (n = 100), m 305 ± 126 306 ± 138 332 ± 115 279 ± 129 0.145
Outcome by December 31, 2012
Follow-up days 979 ± 870 1,425 ± 1,410 1,236 ± 831 589 ± 395
Alive 59 (47) 1 (5) 21 (40) 37 (66)
Dead 52 (41) 13 (68) 24 (46) 15 (27)
Lung transplantation 8 (6) 3 (16) 3 (6) 2 (4)
Lost to follow-up 8 (6) 2 (11) 4 (8) 2 (4)
Target therapy 
Therapy started within 3 months
No drug 55 (43) 6 (32) 27 (52) 22 (39)
Single drug 65 (51) 12 (63) 24 (46) 29 (52)
Double combination 7 (6) 1 (5) 1 (2) 5 (9)
Triple combination 0 0 0 0
ERA 44 (35) 8 (42) 17 (33) 19 (34)
Prostanoid 8 (6) 4 (21) 3 (6) 1 (2)
PDE5-I 27 (21) 2 (11) 6 (12) 19 (34)
Maximal therapy 
No drug 36 (28) 3 (16) 8 (35) 15 (27)
Single drug 62 (50) 8 (42) 25 (48) 29 (52)
Double combination 24 (19) 7 (37) 8 (15) 9 (16)
Triple combination 5 (4) 1 (5) 1 (2) 3 (5)
Data are given as means ± SD or numbers with percentages in parentheses.
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 Table 6.  Adult patients by diagnostic group
PAH
(group I)
Left heart 
disease
(group II)
Lung 
disease
(group III)
CTEPH
(group IV)
Miscellaneous
(group V)
p value
overall PAH vs. CTEPH
Demographics
Number 517 35 125 249 35
Females 309 (60) 23 (66) 37 (30) 120 (48) 12 (34)
Age, years 57 ± 16 62 ± 15 67 ± 10 63 ± 13 59 ± 15 0.000 0.000
BMI (n = 120) 26 ± 7 29 ± 7 27 ± 6 27 ± 5 24 ± 5 0.026 0.009
Vital signs and hemodynamics
Heart rate (n = 873), bpm 82 ± 15 77 ± 35 87 ± 20 81 ± 14 83 ± 16 0.005 0.723
Tricuspid gradient (n = 593), mm Hg 67 ± 20 61 ± 15 61 ± 20 66 ± 18 60 ± 13 0.036 0.371
mPAP (n = 960), mm Hg 48 ± 16 42 ± 12 40 ± 10 45 ± 12 42 ± 11 0.000 0.022
Pulmonary artery wedge pressure (n = 883), mm Hg 12 ± 7 20 ± 7 13 ± 7 12 ± 6 13 ± 6 0.000 0.04
Right atrial pressure (n = 820), mm Hg 9 ± 8 10 ± 5 9 ± 9 9 ± 6 8 ± 5 0.937 0.949
PVR (n = 821), dyn/s/m5 753 ± 454 413 ± 238 545 ± 345 767 ± 463 604 ± 446 0.000 0.742
Cardiac index (n = 847), l/min/m2 2.5 ± 0.8 2.7 ± 0.8 2.6 ± 0.6 2.3 ± 0.6 3.0 ± 1 0.000 0.000
Arterial oxygen saturation (n = 837), % 93 ± 5 93 ± 4 89 ± 8 92 ± 4 91 ± 7 0.000 0.022
Mixed venous oxygen saturation (n = 754), % 63 ± 11 66 ± 10 62 ± 11 60 ± 10 65 ± 9 0.003 0.911
Functional capacity
NYHA mean (n = 834) 2.9 ± 0.7 2.7 ± 0.5 3.0 ± 0.7 3.0 ± 0.7 3.0 ± 0.7 0.139 0.764
6MWD (n = 785), m 362 ± 137 377 ± 149 305 ± 127 365 ± 138 357 ± 144 0.003 0.476
Outcome by December 31, 2012
Follow-up days 1,393 ± 1,337 973 ± 1,081 974 ± 871 1,313 ± 1,158 978 ± 933
Alive 271 (52) 22 (63) 58 (46) 138 (55) 16 (46)
Dead 191 (37) 8 (23) 52 (42) 58 (23) 12 (34)
Lung transplantation 20 (4) 0 6 (5) 4 (2) 5 (14)
Lost to follow-up 34 (7) 5 (14) 8 (6) 15 (6) 2 (6)
Data are given as means ± SD or numbers with percentages in parentheses.
Diagnostic PH group
PAH
PH in left heart disease
PH in chronic lung disease
CTEPH
Miscellaneous
PAH – censored
PH in left heart disease – censored
PH in chronic lung disease – censored
CTEPH – censored
Miscellaneous – censored
p < 0.05 in lung diseases vs. PAH/CTEPH
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 Fig. 6. Kaplan-Meier survival curves by di-
agnosis for adult patients with PH by their 
diagnostic group. 
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cident cases were included. This article describes the 
changing epidemiology of the PH disease spectrum over 
predefined time periods. 
 Changes in PH Epidemiology over Time 
 The registry survived different PH classifications ac-
cording to the WHO  [1, 19] ; however, for the vast major-
ity of patients the 5 diagnostic groups as specified by the 
registry still apply. Over all PH groups, age increased 
over time and the predominance of females decreased 
towards an almost equal gender distribution during the 
last incident period. The same trend was found for PAH. 
This is in line with others, which also found that age at 
diagnosis increased from a mean age of 34 years in the 
NIH cohort to around 55 in French, British and Ameri-
can cohorts  [7–9, 14–16, 21] . The mean age of CTEPH 
also increased over time periods; however, the signifi-
cance could be attributed to the time before 2000, where 
also incident patients were included. Overall, age in our 
CTEPH cohort was comparable to the ASPIRE cohort 
(63 ± 14 vs. 70 ± 12 and 63 ± 16 years for not operated 
and nonoperable patients, respectively) and the inter-
national CTEPH registry (63 years)  [11] . Overall, the 
BMI increased over incident time periods but not if 
PAH, CTEPH and PH in lung diseases were analyzed 
separately. 
 Among all PH patients registered, the percentage of 
PAH group I decreased over the incident time periods, 
whereas other groups increased. This is most probably 
related to an increased awareness by treating physicians 
of severe PH in heart, lung and thromboembolic diseases. 
Since the Swiss PH registry was kept by PH referral cen-
ters, the majority of PH due to chronic heart and lung 
diseases had severe PH and thus may not represent the 
whole spectrum of these two groups. Within the PAH 
group I, the percentage of adult patients with idiopathic 
PAH increased, whereas associated PAH slightly de-
creased. One reason for the decrease in associated PAH 
might be attributed to the lower number of children reg-
istered recently. The percentage of idiopathic (including 
heritable) PAH was slightly higher compared to the 
French registry, the percentage of portal hypertension 
and HIV-associated PAH was clearly lower (5 and 7% vs. 
10 and 6%), with an even greater difference when looking 
at incident cases during similar time periods (4 and 3% 
vs. 15 and 10%)  [16] . In comparison to the REVEAL reg-
istry  [9] , our proportion of idiopathic cases was slightly 
higher (60 vs. 46%) and that of congenital heart disease-
associated PAH lower. It is not known whether these dif-
ferences can be attributed to referral or diagnostic biases 
or whether they reflect true epidemiological differences 
between different countries.
 Differences in PH Disease Characteristics 
 The majority of patients registered were in NYHA 
class III, and there were no differences between the major 
diagnostic groups and time periods. This is in line with 
other registries including different PH classifications  [7] . 
However, the percentage of NYHA class I and II patients 
vastly differs between registries, e.g. 1/4 of patients in our 
cohort and the French registry, 1/6 in the UK registry, 
>1/3 in the REVEAL registry and 1/5 in the ASPIRE reg-
istry  [7–9, 16] . The overall mean 6MWD at diagnosis was 
357 m, with comparable values for most PH groups with 
the exception of PH due to patients with chronic lung dis-
eases, who walked significantly less. This is in line with 
other registries including patients over all NYHA classes 
 [8, 9] . The overall mPAP and PVR were in line with oth-
er registries  [7] . The mPAP of the PAH group was slight-
ly lower compared to that of the REVEAL and UK reg-
istries (48 vs. 55 and 54 mm Hg)  [8, 9] and in line with 
incident PAH patients in the French registry  [16] . The 
mPAP and PVR significantly decreased over incident pe-
riods, whereas the peripheral blood pressure increased. 
Both the mPAP and the cardiac output were significantly 
higher in PAH compared with CTEPH, resulting in a 
similar PVR. A higher cardiac output in PAH than in 
CTEPH was also found in the ASPIRE and Spanish reg-
istries  [7, 10] . The arterial oxygen saturation was signifi-
cantly lower in CTEPH than PAH and lowest in PH due 
to lung diseases. The mixed venous oxygen saturation 
was similar in our PAH compared to other PAH registries 
 [8, 16] .
 PH Target Therapies by Diagnostic Group 
 In 59% of the PAH patients, target therapy was started 
with one drug, 10% received initial double and 3% triple 
combination therapy. The majority started with ERA or 
PDE5-I (52 or 22%), with increasing proportions over 
time, prostanoids were initially given in 14%, with a de-
creasing proportion over time. An initial CCB was given 
in 7% of all PAH cases with a decreasing proportion over 
time. Comparable trends for initial treatment changes 
were found in the British registry, with differences in ab-
solute percentages of drug use, albeit time periods ana-
lyzed did not exactly correspond  [8] . In comparison to 
British and American patients, PAH-specific therapy in 
Switzerland is more often started with an ERA and slight-
ly less frequently with PDE5-I and prostanoids  [8, 9, 21] . 
Out of all adult PAH patients registered over the entire 
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period, 89% received PAH target therapies, from these 
43% combination therapies. The overall proportion is 
comparable to that of the ASPIRE registry, but Swiss
patients received more combination therapies (26 vs. 
46%)  [7] .
 Out of all 249 CTEPH patients registered, only 34 
(14%) had endarterectomy with a slightly increasing rate 
over time. Four patients underwent lung transplantation 
in earlier periods. Unfortunately, the registry does not 
provide whether this major part of nonoperated CTEPH 
patients was surgically inaccessible or which other rea-
sons resulted in conservative management. This should 
be analyzed in the future. The percentage of nonoperated 
CTEPH patients is herewith strikingly higher compared 
with other registries and warrants medical action  [7, 10, 
11] . One reason might be the absence of a dedicated pul-
monary endarterectomy center during that time in Swit-
zerland, a small country with 8 million inhabitants poten-
tially below the critical yearly case number. Nevertheless, 
major PH centers in Switzerland work in close collabora-
tion with pulmonary endarterectomy centers in adjacent 
countries  [11, 22] . However, treatment abroad for a very 
serious surgery might not be accepted by Swiss patients 
or insurance providers and be associated with adminis-
trative burdens for caregivers. 73% of the nonoperated 
CTEPH patients received PAH target therapies within 3 
months of diagnosis, hereof 8% combination therapies, 
with increasing percentage over time. The majority of 
the nonoperated CTEPH patients received ERA, fewer 
PDE5-I and prostanoids. This is in line with other regis-
tries  [7, 11] . 
 Of PH cases due to lung disease registered, half start-
ed off-label PAH target therapy and 6% even combina-
tion therapy. Over the whole period, the proportion 
treated with PAH target therapy increased to 71% and 
was herewith higher than in the ASPIRE registry (47%) 
 [7] .
 Event-Free Survival 
 In all diagnostic groups, event-free survival was sig-
nificantly better for the first period including prevalent 
patients compared to later periods with incident cases. 
This is known from other registries which showed a better 
prognosis of prevalent cases due to selection bias  [6, 23] . 
Our registry provides data from different PH classifica-
tions over predefined time periods. In all diagnostic 
groups, event-free survival was similar over incident pe-
riods. When looking only at PAH, event-free survival has 
been better since 2005, despite the higher ages of the pa-
tients. This might be explained by emerging treatment 
options, an increased awareness of the disease or a better 
care. The survival in the Swiss PAH collective was com-
parable to that of other registries  [8, 9, 16] .
 The overall survival in nonoperated CTEPH patients 
was lower compared with cohorts reported from Sheffield 
or Spain, where half of the patients were operated  [7, 10] , 
but comparable to nonoperated patients  [7, 24] . This 
clearly indicates that Switzerland has to make a clear ef-
fort to get more patients operated.
 As in other cohorts, survival of patients with PH due 
to lung diseases was worse compared to other PH groups 
and comparable with the ASPIRE cohort, one of the few 
cohorts reporting on this group  [7] .
 It has been known for a long time that severe PH is rare 
but associated with a dismal prognosis in lung disease  [25, 
26] . With an mPAP of 40 mm Hg, the PH in lung disease 
reported here, these patients were severely affected. Of 
these patients, 70% received PH target therapy, although 
such therapies have never been studied in a randomized 
trial  [27] . Part of the PH associated with the chronic ob-
structive lung disease collective of the ASPIRE registry 
was treated with PH target therapy, and an improved out-
come in those who responded with PVR reduction could 
be demonstrated  [28] . Their prognosis was clearly worse 
compared to other diagnostic groups. This finding under-
scores the need for research and well-designed trials in 
order to develop effective therapies for PH in lung dis-
eases.
 PH due to heart disease was classified in a very small 
group (3.6%) only. As in other registries, this group tend-
ed to have a better survival at the beginning; the small 
number does not allow conclusions from long-term sur-
vival analysis in this group.
 Limitations 
 Registries are important to characterize populations, 
assess the burden of diseases and describe practice pat-
terns. In contrast to a prospective study, registries do usu-
ally not provide a schedule of data entry or allow includ-
ing patients only according to predefined data sets. Thus, 
this registry rather reflects the real world, and it may 
therefore be that classification and data quality vary be-
tween centers. Other limitations of registries are the fol-
lowing: due to lack of randomization, registry data are 
prone to confounders, selection bias, and thus, compari-
son between registries with different inclusion/exclusion 
criteria has to be made with caution. 
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 Conclusion 
 Taken together, the long-term follow-up provided by 
the Swiss PH registry offers the opportunity for real-life 
epidemiological data. The data shown here emphasize 
that over time periods, incident PH patients are older 
with an equal sex distribution. Survival was better for 
PAH diagnosed since 2008 compared with earlier periods 
and better for PAH and CTEPH compared with PH due 
to lung disease. The vast majority of PAH and CTEPH 
patients were treated with PAH target therapies, 43% 
even with combination therapy.
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Erratum
The authors of the article entitled ‘Long-term data from the Swiss pulmonary hyperten-
sion registry’ [Respiration 2015;89:127–140, DOI: 10.1159/000370125] wish to publish the 
following correction. On page 127, the name of an author has been published incorrectly: 
Guido Domeninghetti should read Guido Domenighetti. The correct author list should 
be as follows:
Séverine Mueller-Motteta  Hans Strickerb  Guido Domenighettic
Andrea Azzolad  Thomas Geisere  Markus Schwerzmannf  Daniel Weilenmanng
Otto Schochh  Jean-Marc Fellrathi  Thierry Rochatj  Frederic Ladorj
Maurice Beghettik  Laurent Nicodl  John-David Aubertl  Vladimir Popovm
Rudolf Speicha  Stephan Keuscha  Elisabeth Haslera  Lars C. Hubera
Peter Grendelmeiern  Michael Tammn  Silvia Ulricha
aPulmonary Clinic, University Hospital Zurich, Zurich, bClinic of Internal Medicine, Os-
pedale La Carità, and cPulmonary Clinic, Cantonal Hospital Locarno, Locarno, dPulmo-
nary Clinic, Cantonal Hospital Lugano, Lugano, ePulmonary Clinic and fDivision of Car-
diology, University Hospital Bern, Bern, gDivision of Cardiology and hPulmonary Clinic, 
Cantonal Hospital St. Gallen, St. Gallen, iPulmonary Clinic, Cantonal Hospital Neuchâtel, 
Neuchâtel, jPulmonary Clinic, University Hospital Geneva, and kPediatric Cardiology 
Unit, University Children’s Hospital, Geneva, lPulmonary Clinic, University Hospital 
Lausanne, Lausanne, mPulmonary Clinic, Cantonal Hospital Lucerne, Lucerne, and nPul-
monary Clinic, University Hospital Basel, Basel, Switzerland
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